Tech Center 1600 • Art Units: 1634 1682
This examiner grants 53% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18434556 | NOVEL IMMUNOPROBE-BASED METHOD TO ASSESS ORGAN INJURY STATUS THROUGH A BIOFLUID-BASED CELL-FREE DNA (CFDNA) ASSAY | Non-Final OA | The Regents of the University of California |
| 19087361 | METHODS AND MATERIALS FOR ASSESSING LOSS OF HETEROZYGOSITY | Non-Final OA | Myriad Genetics, Inc. |
| 17822332 | TARGETED MEASURE OF TRANSCRIPTIONAL ACTIVITY RELATED TO HORMONE RECEPTORS | Non-Final OA | Yale University |
| 18673186 | MULTIPLEX DETECTION OF VULVOVAGINAL CANDIDIASIS, TRICHOMONIASIS AND BACTERIAL VAGINOSIS | Final Rejection | Becton, Dickinson and Company |
| 18008053 | IMMUNOGENIC RETROELEMENTS AND THEIR USE IN CANCER THERAPY | Non-Final OA | UNIVERSITY HEALTH NETWORK |
| 18316719 | ASSAYS AND METHODS FOR SELECTING A TREATMENT REGIMEN FOR A SUBJECT WITH LEUKEMIA | Non-Final OA | Oregon Health & Science University |
| 18067194 | CELL-BASED DNA SENSORS AND METHODS OF USING SAME | Final Rejection | Wisconsin Alumni Research Foundation |
| 18158732 | GENE FUSIONS AND GENE VARIANTS ASSOCIATED WITH CANCER | Non-Final OA | Life Technologies Corporation |
| 16863360 | CLASSIFICATION AND ACTIONABILITY INDICES FOR CANCER | Final Rejection | LIFE TECHNOLOGIES CORPORATION |
| 18087426 | Methods and Compositions for Diagnosis and Treatment of Disorders in Pets | Final Rejection | Hill's Pet Nutrition, Inc. |
| 17907774 | COMPOSITIONS AND METHODS FOR DETECTING BCL2L14 AND ETV6 GENE FUSIONS FOR DETERMINING INCREASED DRUG RESISTANCE | Non-Final OA | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION |
| 17576307 | COMPOSITIONS AND METHODS FOR DISCRIMINATING BACTERIAL AND VIRAL INFECTIONS IN A HUMAN SUBJECT | Final Rejection | Cepheid |
| 16973414 | METHOD FOR DETECTING A TANDEM REPEAT | Non-Final OA | IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE |
| 17813647 | METHODS FOR THE COMPREHENSIVE IDENTIFICATION OF ANTIMICROBIAL RESISTANCE MARKERS BY SEQUENCING | Final Rejection | bioMérieux |
| 18423938 | METHODS AND COMPOSITIONS FOR TREATING LIVER CANCER AND LIVER DISEASE | Final Rejection | Active Genomes Expressed Diagnostics Corp |
| 18016601 | PROGNOSTIC BIOMARKERS FOR CANCER | Non-Final OA | UNIVERSITÄT BERN |
| 18407073 | KITS AND METHODS FOR DIAGNOSING LUNG CANCER | Non-Final OA | NUCLEIX LTD. |
| 17274126 | BIOMARKERS FOR CANCER THERAPY | Non-Final OA | The Council of the Queensland Institute of Medical Research |
| 18032492 | METHODS FOR TREATMENT OF LUNG CANCERS | Final Rejection | Mirati Therapeutics, Inc. |
| 16902552 | Systems And Methods For Treating Patients Having A Genetic Predisposition To Develop Prostate Cancer | Final Rejection | Institute For Cancer Research d/b/a The Research Institute Of Fox Chase Cancer Center |
| 18280801 | COMPOSITION FOR DIAGNOSING PANCREATIC CANCER | Non-Final OA | ACURASYSBIO CO., LTD. |
| 18546939 | USE OF ABCF1 IN METHODS OF DIAGNOSING AND MONITORING INFLAMMATORY AND/OR AUTOIMMUNE DISEASE | Non-Final OA | MYND Life Sciences Inc. |
| 18068517 | COMPANION DIAGNOSTIC BIOMARKERS OF EGFR INHIBITOR | Non-Final OA | KOREA FOOD & DRUG ADMINISTRATION |
| 17620573 | POLYMORPHISMS AS PREDICTORS OF TREATMENT RESPONSE AND OVERALL SURVIVAL OF METASTATIC COLORECTAL CANCER | Non-Final OA | AENORASIS COMMERCIAL COMPANY OF PHARMACEUTICAL AND MEDICAL PRODUCTS AND MACHINES SOCIETE ANONYME |
| 17553299 | LIPOSOMAL PREPARATIONS FOR NON-INVASIVE-PRENATAL OR CANCER SCREENING | Final Rejection | SeraCare Life Sciences, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy